Severe, Prolonged, Denosumab-Induced Hypocalcemia With Recovery After 111 Days Of High-Dose Calcium Supplementation
AACE clinical case reports（2019）
摘要
Objective: Denosumab is a monoclonal antibody commonly used for the prevention of skeletal-related events in patients with bone metastases from solid tumors. Hypocalcemia is a known adverse effect with denosumab, and we present an unusual case where 2 hypocalcemic events occurred after 1 denosumab treatment.
更多查看译文
关键词
Denosumab,Metastatic Bone Disease
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要